Project Details
Description
PROJECT SUMMARY
Antibody-dependent enhancement (ADE) is a phenomenon by which antibodies raised in response to a primary
infection cross-react to a similar pathogen during a subsequent infection, resulting in increased viral load and
severity of disease. ADE of Zika virus (ZIKV) infection by preexisting DENV antibodies has been hypothesized
to play a role in the severe adverse pregnancy outcomes observed following congenital ZIKV infection. ADE is
mediated by interactions between virus-bound IgG antibodies and Fc gamma receptors (FcRs) on host cells. In
humans, a nonsynonymous single nucleotide polymorphism (SNP) in FCGR2A, rs1801274, results in an amino
acid change at site 131 from arginine (Arg131) to histidine (His131) in the IgG-binding region of FcRIIA. Previous
work in vitro has shown that cells expressing the His131 receptor variant bind human IgG1 and IgG2 with
significantly higher affinity than those expressing the Arg131 receptor variant. We hypothesize that individuals
homozygous for the high affinity His131 allele will be at greater risk for ADE of viral infection than individuals
homozygous for the low affinity Arg131 allele. In this application, we will assess the effect of this SNP on ADE
of ZIKV using cell lines derived from K562 cells that are homozygous for the Arg131 or His131 allele and primary
human monocytes that will be stratified by genotype (Aim 1). We have also generated IgG subclass switch
variants of a flavivirus-reactive monoclonal antibody that we will use to assess the role of each IgG subclass in
mediating ADE of ZIKV through the different FcRIIA variants using His131 and Arg131 homozygous K562 cell
lines, primary human monocytes, and Hofbauer cells isolated from full term human placentas (Aim 2). A
comprehensive understanding of host genetic factors that affect susceptibility to ADE, including those described
in this proposal, may help to identify populations at increased risk of developing severe disease as a result of
ZIKV infection, particularly among pregnant women. The proposed project provides an excellent opportunity for
training that encapsulates traditional virology and immunology techniques, professional development, and
mentorship that will support the applicant’s growth as an independent academic scientist.
Status | Active |
---|---|
Effective start/end date | 17/03/21 → 16/03/23 |
Funding
- National Institute of Allergy and Infectious Diseases: $44,436.00
- National Institute of Allergy and Infectious Diseases: $44,436.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.